NCT04673162 is a Phase 3 clinical trial of Methylprednisolone, Placebo in Covid19, sponsored by Azienda USL Reggio Emilia - IRCCS.

Who is sponsoring NCT04673162?

NCT04673162 is sponsored by Azienda USL Reggio Emilia - IRCCS.

What drugs are being tested in NCT04673162?

Interventions in NCT04673162: Methylprednisolone, Placebo.

Is NCT04673162 still recruiting?

NCT04673162 is currently completed. Last updated 23 May 2022.

Last reviewed 2022-05-23 · How we verify

NCT04673162

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients

Completed Phase 3 Last updated 23 May 2022

What this trial tests

Phase 3 trial testing Methylprednisolone, Placebo in Covid19 in 260 participants. Completed in 12 July 2021.

Timeline

17 December 2020

Primary endpoint
21 April 2021

12 July 2021

Quick facts

Lead sponsor	Azienda USL Reggio Emilia - IRCCS
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	260
Start date	17 December 2020
Primary completion	21 April 2021
Estimated completion	12 July 2021
Sites	20 locations across Italy

Drugs / interventions tested

Methylprednisolone, Placebo

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Azienda USL Reggio Emilia - IRCCS — full company profile →

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This double blind, randomized study is aiming to evaluate the efficacy of three doses (1gr/day) of methylpredisolone added to standard therapy in patients, with documented COVID-19 pneumonia, requiring hospitalization but not mechanical ventilation.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Systemic corticosteroids for the treatment of COVID-19.
Wagner C, Griesel M, Mikolajewska A, Mueller A, et al · · 2021 · cited 151× · PMID 34396514 · DOI 10.1002/14651858.cd014963
Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence.
Wagner C, Griesel M, Mikolajewska A, Metzendorf MI, et al · · 2022 · cited 44× · PMID 36385229 · DOI 10.1002/14651858.cd014963.pub2
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial.
Salvarani C, Massari M, Costantini M, Merlo DF, et al · · 2022 · cited 42× · PMID 35361632 · DOI 10.1183/13993003.00025-2022
Mast cells: Therapeutic targets for COVID-19 and beyond.
Lam HY, Tergaonkar V, Kumar AP, Ahn KS. · · 2021 · cited 17× · PMID 34467628 · DOI 10.1002/iub.2552
Effect of corticosteroids in patients with COVID-19: a Bayesian network meta-analysis.
Wang X, Wen D, He Q, Yang J, et al · · 2022 · cited 11× · PMID 36272700 · DOI 10.1016/j.ijid.2022.10.021

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Azienda USL Reggio Emilia - IRCCS trials

Trials by the same sponsor.

NCT07373626 — Physical Activity Trends in Cancer Survivors Treated at the 'MOvement and REhabilitation' Clinic · recruiting
NCT07000162 — LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial · Phase 2 · recruiting
NCT06629896 — Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomize · NA · recruiting
NCT06749600 — Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma · recruiting
NCT06624280 — Does Orthopedic Surgery Improve Gait Efficiency in Children With Cerebral Palsy? A Retrospective Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04673162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda USL Reggio Emilia - IRCCS
Last refreshed: 23 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04673162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing